The population approach to modeling and NONMEM are used to develop structural and statistical pharmacokinetic and pharmacodynamic models. Patient demographics are probed as potential covariates for pharmacokinetic and/or pharmacodynamic parameters. The objective of the research is to identify patient characteristics that result in altered pharmacokinetic or pharmacodynamic parameters and to allow optimum drug doses to be identified in diverse patient groups. The research has involved drugs from many different therapeutic areas. A list of selected publications is provided below.
- Jackson, K.A., Rosenbaum, S.E., Yuen, G., Pipavola, Y., Kerr, B. and Dudley M.N. A Population Pharmacokinetic Analysis of Nelfinavir Mesylate in Human Immunodeficiency Virus (HIV) Infected Patients Enrolled in a Phase III Clinical Trial. Antimicrobial Agents and Chemotherapy. 44, 1832-1837, 2000.
- Rosenbaum, S.E., Baheti G., Akhlaghi F., Trull A.K. Population Pharmacokinetics of Cyclosporine in Thoracic Transplant Patients. Therapeutic Drug Monitoring 27 116-122, 2005.
- Rosenbaum S.E, Lee W. and Powell P. Interactive Computer Programs To Teach Clinical Pharmacokinetics and Dose Optimization Methods. J Clin Pharmacol, 46, 1075 2006.
- Population Pharmacokinetics of Mycophenolic Acid and its Two Glucuronidated Metabolites in Kidney Transplant Recipients. Sam, W.J., Akhlaghi, F. and Rosenbaum, S.E. J Clin Pharmacol 49. 185-195, 2009.
- Narwal, R, Akhlaghi, F, Aasberg, A, Herman M and Rosenbaum, S.E. Development of a Population Pharmacokinetic Model for Atorvastatin Acid and its Lactone Metabolite. Clin. Pharmacokinetics, 49 693-702, 2010.